LISATA THERAPEUTICS INC(LSTA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LSTA LISATA THERAPEUTICS INC

休市中 10-02 16:00:00 EDT

1.47

-0.02

-1.34%

盘后1.47

+0.000.00%

19:30 EDT

最高1.50	最低1.47	成交量3,681
今开1.49	昨收1.49	日振幅2.01%
总市值1,588万	流通市值1,241万	总股本1,080万
成交额5,439	换手率0.04%	流通股本843.99万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LSTA","market":"US","secType":"STK","nameCN":"LISATA THERAPEUTICS INC","latestPrice":1.47,"timestamp":1790971200000,"preClose":1.49,"halted":0,"volume":3681,"hourTrading":{"tag":"盘后","latestPrice":1.47,"preClose":1.47,"latestTime":"19:30 EDT","volume":30,"amount":44.3,"timestamp":1790983802643,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01342281879194632,"floatShares":8439900,"shares":10804100,"eps":-1.641822,"marketStatus":"休市中","change":-0.02,"latestTime":"10-02 16:00:00 EDT","open":1.49,"high":1.5,"low":1.47,"amount":5438.5494012,"amplitude":0.020134,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.641822,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1186632000000,"exchange":"NASDAQ","adjPreClose":1.49,"preHourTrading":{"tag":"盘前","latestPrice":1.55,"preClose":1.49,"latestTime":"08:20 EDT","volume":1,"amount":1.55,"timestamp":1790943625987,"change":0.06,"changeRate":0.040268,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.47,"preClose":1.47,"latestTime":"19:30 EDT","volume":30,"amount":44.3,"timestamp":1790983802643,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.08480746065787602},"requestUrl":"/m/hq/s/LSTA","defaultTab":"news","newsList":[{"id":"1198844816","title":"Lisata Therapeutics投资者将获得每股1,491.37美元的15万零867.995股C系列优先股","url":"https://stock-news.laohu8.com/highlight/detail?id=1198844816","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198844816?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:34","pubTimestamp":1789652062,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics的投资者即将迎来一项重大权益分配——他们将收到总计150,867.995股C系列优先股，每股作价1,491.37美元。从交易执行角度看，每股1,491.37美元的定价方案已获董事会批准，预计将在既定时间框架内完成结算流程。此次分配完成后，公司总股本结构将发生相应变化，现有普通股股东的稀释效应有待进一步评估。Lisata Therapeutics作为一家专注于创新癌症疗法的生物制药企业，其股价近期的波动走势与行业政策环境、临床试验数据等因素紧密相连。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181729718","title":"Lisata Therapeutics交易后股权结构揭晓：Lisata原股东持2.39%，Marea股东持59.54%，投资者持38.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181729718","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181729718?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:28","pubTimestamp":1789651693,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics近期完成了一项重大交易，其股权结构随之发生了显著变化。据最新披露的数据显示，在这笔交易尘埃落定之后，Lisata Therapeutics原有股东在公司普通股中的持股比例已降至2.39%。与此同时，Marea股东则占据了绝对主导地位，其持股比例高达59.54%。此外，参与此次交易的投资者群体合计持有公司38.07%的普通股。整体而言，这一股权分配方案，将为Lisata Therapeutics未来的公司治理、决策机制以及资本运作，奠定一个全新的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101487698","title":"Lisata Therapeutics：全股票交易收购方案，涉及普通股与C轮优先股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101487698","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101487698?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:28","pubTimestamp":1789651690,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics宣布了一项收购计划，该交易被设计为全股票交易，具体将采用Lisata普通股及C轮优先股作为对价方式。这一结构安排意味着，收购方将通过换股形式完成整合，而非现金支付。值得注意的是，此次交易中，Lisata的普通股与C轮优先股均扮演了关键角色，二者共同构成了交易的对价基础。这一决策，无疑为股东们提供了另一种价值实现的途径——通过持有合并后实体的股份来分享未来增长成果。整个交易方案，从设计之初便体现了对现有股东利益的考量，力求在资本结构上实现平稳过渡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143952601","title":"Lisata Therapeutics拟动用净收益推进MAR001/005与MAR002项目，二期关键数据预计2027年第四季度揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1143952601","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143952601?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:28","pubTimestamp":1789651690,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics宣布，将通过动用本次募资所得净收益，全力推进旗下两大核心管线——MAR001/005及MAR002的临床研发进程。根据公司披露的时间表，上述两项在研疗法的二期临床试验顶线数据，预计将在2027年第四季度对外公布。截至目前，Lisata并未透露更多关于资金分配的具体细节，但明确表示净收益将优先用于支撑上述临床项目的推进，以确保关键里程碑的如期达成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188029638","title":"Lisata Therapeutics宣布收购Marea Therapeutics并同步完成2.25亿美元私募融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1188029638","media":"美股速递","labels":["shareholding","corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188029638?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:27","pubTimestamp":1789651636,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics今日正式对外宣布，公司已就收购Marea Therapeutics达成最终协议。与此同时，该公司还顺利敲定了一笔总额高达2.25亿美元的同步私募融资安排。从战略层面审视，收购Marea Therapeutics无疑是Lisata布局未来的一大步棋。通过整合双方资源与技术平台，Lisata有望在相关治疗领域构筑起更为坚实的竞争壁垒。未来，随着整合工作的有序推进，Lisata Therapeutics将如何续写其创新药开发的新篇章，各界正拭目以待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195250038","title":"Lisata Therapeutics董事会持续评估战略选项，旨在提升股东价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1195250038","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195250038?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:02","pubTimestamp":1785841335,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics董事会，正持续审视各类战略替代方案，核心目标在于为股东创造更大价值。这一进程，不仅展现了公司对资本配置的审慎态度，更映射出其对市场动态的敏锐洞察。在竞争激烈的生物医药领域，此类评估往往成为企业转型或价值重估的关键节点。未来，无论是通过并购、资产剥离，还是业务重组，任何决策都将以股东利益最大化为核心导向。目前，董事会正深入分析多种可能性，以确保持续优化公司结构，进而释放其潜在价值。这一举措，无疑为市场注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157880865","title":"Lisata Therapeutics 预估：截至2026年9月30日季度内，裁员相关成本达120万美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1157880865","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157880865?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:11","pubTimestamp":1785838281,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会（SEC）文件披露，Lisata Therapeutics（证券代码：LSTA）对其财务状况进行了最新预估。该公司预计，在截至2026年9月30日的季度内，与其裁员计划相关的总成本将高达120万美元。这一数字涵盖了此次人力资源调整所产生的各项直接与间接费用，正式揭开了企业战略收缩下的财务影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150579973","title":"Lisata Therapeutics 于7月31日就Kuva Labs及Kuva Acquisition Corp.违反合并协议提起法律诉讼——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1150579973","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150579973?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:11","pubTimestamp":1785838270,"startTime":"0","endTime":"0","summary":"LISATA THERAPEUTICS INC（股票代码：LSTA）——根据其向美国证券交易委员会提交的文件，该公司已于7月31日正式启动法律程序，针对Kuva Labs与Kuva Acquisition Corp.违反合并协议的行为提起诉讼。此项行动标志着双方合作破裂后的法律升级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186569662","title":"Lisata Therapeutics宣布：自2026年8月3日起，终止Kristen K. Buck研发执行副总裁兼首席医疗官职务——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1186569662","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186569662?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:10","pubTimestamp":1785838210,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics（公司名：LISATA THERAPEUTICS INC）——据美国证券交易委员会（SEC）最新提交的文件显示，该公司已正式决定，自2026年8月3日起，终止Kristen K. Buck担任的研发执行副总裁（Evp of R&D）兼首席医疗官（Chief Medical Officer）职务。此举标志着公司高层管理团队的重大调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199900895","title":"Lisata Therapeutics裁员约72% 即刻生效——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1199900895","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199900895?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:09","pubTimestamp":1785838157,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会（SEC）文件显示，Lisata Therapeutics于8月3日批准了一项大规模裁员计划。该计划将裁减约72%的员工，且自批准之日起立即生效。这一削减力度极为显著，涉及公司内部多个岗位。目前，公司并未透露此次裁员的具体原因及后续补偿方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186264845","title":"Lisata Therapeutics董事会评估战略选项，考虑反向并购或资产出售","url":"https://stock-news.laohu8.com/highlight/detail?id=1186264845","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186264845?lang=zh_cn&edition=full","pubTime":"2026-07-25 00:18","pubTimestamp":1784909889,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics公司于美国证券交易委员会（SEC）提交的文件中披露，其董事会正着手评估一系列战略选项。这些备选方案包括反向并购、资产出售等可能性。此举预示着这家生物制药企业或将迎来重大结构变革。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140137974","title":"Lisata Therapeutics：若满足特定条件，公司将放弃追索25万美元逾期付款的权利——SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1140137974","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140137974?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:36","pubTimestamp":1781004988,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，生物技术公司Lisata Therapeutics表示，如果满足特定条件，它将放弃就一笔25万美元的逾期付款提出索赔的权利。该文件披露了公司与相关方就付款义务进行的协商与调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157369426","title":"Lisata Therapeutics与Kuva Labs达成和解协议 承诺在2026年5月29日前暂停追索权","url":"https://stock-news.laohu8.com/highlight/detail?id=1157369426","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157369426?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:08","pubTimestamp":1777889296,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会文件显示，生物制药企业Lisata Therapeutics Inc已与Kuva Labs达成具有约束力的法律协议。该协议明确规定，在2026年5月29日之前，Lisata将暂缓对Kuva Labs采取任何形式的索赔追索行动。文件未透露双方争议的具体细节，但明确记载了截止日期具有法律效力。资本市场通常对此类阶段性和解持积极看法，因其能有效避免诉讼成本并维持商业关系的稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188280634","title":"Lisata Therapeutics与Kuva Labs将股权收购要约截止日期延至2026年4月13日——美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1188280634","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188280634?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:05","pubTimestamp":1775210715,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会（SEC）的文件，生物制药公司Lisata Therapeutics Inc（以下简称\"Lisata Therapeutics\"）与其合作伙伴Kuva Labs已共同决定，将此前发起的股权收购要约截止日期正式延长至2026年4月13日。\n这一调整意味着潜在投资者现拥有更充裕的时间来评估并参与此次收购行动。延期举措通常反映出交易双方对达成最终协议的持续诚意，同时也为市场留出更充分的响应窗口。\n业内观察人士指出，此类要约期限的延长可能基于多重因素，包括当前市场条件、投资者反馈或交易细节的进一步优化需求。截至公告发布时，双方未披露更多具体条款变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517466947","title":"Lisata Therapeutics, Inc.2024财年实现净利润-19.99百万美元，同比增加4.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517466947","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517466947?lang=zh_cn&edition=full","pubTime":"2025-03-08 02:00","pubTimestamp":1741370441,"startTime":"0","endTime":"0","summary":"3月8日，Lisata Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-19.99百万美元，同比增加4.08%；其中营业收入为1000000.00美元，每股基本收益为-2.40美元。从资产负债表来看，Lisata Therapeutics, Inc.总负债5.69百万美元，其中短期债务137000.00美元，资产负债比为6.16，流动比率为6.17。机构评级：截至2025年3月8日，当前有3家机构对Lisata Therapeutics, Inc.目标价做出预测，其中目标均价为17.00美元，其中最低目标价为15.00美元，最高目标价为21.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308020042abed9a84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308020042abed9a84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LSTA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517288449","title":"Lisata Therapeutics, Inc.盘中异动 股价大涨8.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517288449","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517288449?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:13","pubTimestamp":1741198384,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时13分，Lisata Therapeutics, Inc.股票出现波动，股价急速拉升8.84%。Lisata Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.38%。Lisata Therapeutics, Inc.公司简介：Lisata Therapeutics Inc是一家临床阶段的生物制药公司，致力于发现、开发和商业化用于治疗晚期实体瘤和其他重大疾病的创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306021304963b0d55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306021304963b0d55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LSTA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514356932","title":"Lisata Therapeutics(LSTA.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.55美元，前值为-0.66美元，预期值为-0.76美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514356932","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514356932?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:00","pubTimestamp":1740693657,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics(LSTA.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.55美元，前值为-0.66美元，预期值为-0.76美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28060048442427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LSTA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137320550","title":"Lisata Therapeutics 第四季度 GAAP 每股收益 $(0.55) 超出 $(0.79) 的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1137320550","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137320550?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:00","pubTimestamp":1740693652,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics  报告季度每股亏损 $，超出分析师一致预期的 $，超出预期 30.38%。与去年同期每股亏损 $ 相比，这是一种 16.67% 的改善。以上内容来自Benzinga Earnings专栏，原文如下：Lisata $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 30.38 percent. This is a 16.67 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385668","title":"Lisata Therapeutics, Inc.盘中异动 早盘急速拉升5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385668","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385668?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:44","pubTimestamp":1740667494,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时44分，Lisata Therapeutics, Inc.股票出现异动，股价急速拉升5.44%。Lisata Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Lisata Therapeutics, Inc.公司简介：Lisata Therapeutics Inc是一家临床阶段的生物制药公司，致力于发现、开发和商业化用于治疗晚期实体瘤和其他重大疾病的创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224454a2567d97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224454a2567d97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LSTA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514075859","title":"Lisata Therapeutics, Inc.盘中异动 股价大跌7.28%报2.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514075859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514075859?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:04","pubTimestamp":1740582251,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时04分，Lisata Therapeutics, Inc.股票出现波动，股价急速跳水7.28%。Lisata Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为4662.94%、160.61%、143.94%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Renovaro Inc.，振幅分别为155.93%、39.47%、29.31%。Lisata Therapeutics, Inc.公司简介：Lisata Therapeutics Inc是一家临床阶段的生物制药公司，致力于发现、开发和商业化用于治疗晚期实体瘤和其他重大疾病的创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262304119893b141&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262304119893b141&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LSTA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lisata.com","stockEarnings":[{"period":"1week","weight":-0.0696},{"period":"1month","weight":-0.0637},{"period":"3month","weight":-0.5586},{"period":"6month","weight":-0.7072},{"period":"1year","weight":-0.4235},{"period":"ytd","weight":-0.2097}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lisata Therapeutics, Inc.根据美国特拉华州法律在Fidelity Medical Services, Inc.的名义下于1980年9月18日注册成立，并于2006年1月在当前市场开始运营。该公司是一家临床阶段的制药公司，致力于发现、开发和商业化治疗实体瘤和其他重大疾病的创新疗法。该公司的主要研究候选产品LSTA1（原名CEND-1）旨在激活一种新的摄取途径，使联合给药或捆绑的抗癌药物能够更有效地穿透实体瘤。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.263077},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.034282},{"month":3,"riseRate":0.727273,"avgChangeRate":0.051032},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.123948},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.00174},{"month":6,"riseRate":0.636364,"avgChangeRate":0.071367},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.109226},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.042316},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.006983},{"month":10,"riseRate":0.25,"avgChangeRate":-0.109378},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.024316},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.083616}],"exchange":"NASDAQ","name":"LISATA THERAPEUTICS INC","nameEN":"LISATA THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LISATA THERAPEUTICS INC(LSTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供LISATA THERAPEUTICS INC(LSTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"LISATA THERAPEUTICS INC,LSTA,LISATA THERAPEUTICS INC股票,LISATA THERAPEUTICS INC股票老虎,LISATA THERAPEUTICS INC股票老虎国际,LISATA THERAPEUTICS INC行情,LISATA THERAPEUTICS INC股票行情,LISATA THERAPEUTICS INC股价,LISATA THERAPEUTICS INC股市,LISATA THERAPEUTICS INC股票价格,LISATA THERAPEUTICS INC股票交易,LISATA THERAPEUTICS INC股票购买,LISATA THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LISATA THERAPEUTICS INC(LSTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供LISATA THERAPEUTICS INC(LSTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}